The Medicines and Healthcare products Regulatory Agency (MHRA) has become the first regulator in the world to approve elinzanetant (Lynkuet) for the treatment of moderate to severe vasomotor symptoms (hot flushes) associated with the menopause.
Further information is available on the gov.uk website.